Skip to main content
Caplight Logo









TOKIWA-Bio Inc.

TOKIWA-Bio Inc.

Private
TsukubaHealthcare & Life Scienceshttps://tokiwa-bio.com/

Last Round

Series B

Oct 20, 2025

Total Funding Raised

$5.47M

Company Overview

TOKIWA-Bio Inc. is a biotechnology company that develops and commercializes its Stealth RNA Vector (SRV) technology for gene therapy, regenerative medicine, and biopharmaceutical manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

Stealth RNA VectorSRVgene deliveryRNA vectornon-viral vectorgene therapycell therapyiPSC reprogrammingnon-integrating vectorregenerative medicinecell reprogramminggene expression systemcustom vector productiondrug discovery servicesresearch reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TOKIWA-Bio Inc. Comparables

Compare TOKIWA-Bio Inc. with similar companies based on industry and business-model similarity.

TOKIWA-Bio Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ReproCELL Incorporated
78%
I'rom Group Co., Ltd.
76%
Eli Lilly and Company
72%

TOKIWA-Bio Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 20, 2025
Series ANov 10, 2017

TOKIWA-Bio Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 12, 2025

    Monthly visitors grew 76% MoM, reaching 2.3K.

  • May 2, 2025

    Monthly visitors increased 281% MoM.

Recent news

Latest coverage and updates

  • is_developingJul 20, 2026

    Tokiwa-Bio Inc. is developing method for generating red blood cell-like cells on Jul 20th '26.

TOKIWA-Bio Inc. Filings

Explore SEC and related filing metadata, where available.

TOKIWA-Bio Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TOKIWA-Bio Inc.'s valuation, stock price, and market status.

Is TOKIWA-Bio Inc. a public or private company?

TOKIWA-Bio Inc. is a private company.

What is the current stock price of TOKIWA-Bio Inc.?

TOKIWA-Bio Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is TOKIWA-Bio Inc. worth (valuation)?

Valuation information for TOKIWA-Bio Inc. is not publicly available.

Can I buy TOKIWA-Bio Inc. stock?

TOKIWA-Bio Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TOKIWA-Bio Inc.'s last funding round?

Funding round information for TOKIWA-Bio Inc. is not publicly available.

Who are the main investors in TOKIWA-Bio Inc.?

Investor information for TOKIWA-Bio Inc. is not publicly disclosed.

Will TOKIWA-Bio Inc. IPO soon?

No public IPO plans have been announced for TOKIWA-Bio Inc..

How can I track TOKIWA-Bio Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TOKIWA-Bio Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTsukuba
Employee Range1
Year Founded2014
Last FundingOct 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?